SIP
BXRX

Stoneridge Investment Partners’s Baudax Bio, Inc. Common Stock BXRX Stock Holding History

Stoneridge Investment Partners’s Portfolio BXRX Stock Details BXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-11
Closed -$3K – 136
2021
Q4 		$3K Hold
11
– – ﹤0.01% 111
2021
Q3 		$8K Hold
11
– – ﹤0.01% 111
2021
Q2 		$11K Hold
11
– – 0.01% 104
2021
Q1 		$19K Hold
11
– – 0.01% 105
2020
Q4 		$15K Buy
+11
New +$22.5K 0.01% 105

Other funds holding BXRX

Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Stoneridge Investment Partners's BXRX Position: Q1 2022 in Review

Stoneridge Investment Partners sold out of Baudax Bio, Inc. Common Stock (BXRX) in Q1 2022, closing a stake of 11 shares — an estimated $3K sold.

Stoneridge Investment Partners first reported a position in BXRX in Q4 2020 and held it in 5 quarters. The position peaked at $19K in Q1 2021. 19 funds tracked by Wall St. Rank hold BXRX as of Q1 2022.

  • Stoneridge Investment Partners reported no remaining Baudax Bio, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Stoneridge Investment Partners sold 11 Baudax Bio, Inc. Common Stock shares in Q1 2022, an estimated $3K.
  • Stoneridge Investment Partners first reported a position in Baudax Bio, Inc. Common Stock in Q4 2020 and held it in 5 quarters.
  • Stoneridge Investment Partners's Baudax Bio, Inc. Common Stock position peaked at $19K in Q1 2021.
  • 19 funds tracked by Wall St. Rank held Baudax Bio, Inc. Common Stock as of Q1 2022.

Based on Stoneridge Investment Partners's 13F filing for Q1 2022, filed 26 Apr 2022.